Abel ED, Gloyn AL, Evans-Molina C, et al. Diabetes mellitus-progress and opportunities in the evolving epidemic. Cell. 2024;187:3789–820.

Article  CAS  PubMed  Google Scholar 

Redondo MJ, Hagopian WA, Oram R, et al. The clinical consequences of heterogeneity within and between different diabetes types. Diabetologia. 2020;63:2040–8.

Article  PubMed  PubMed Central  Google Scholar 

Leslie RD, Ma RCW, Franks PW, Nadeau KJ, Pearson ER, Redondo MJ. Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes. Lancet Diabetes Endocrinol. 2023;11:848–60. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00159-6/abstract.

Stidsen JV, Henriksen JE, Olsen MH.., et al. Pathophysiology-based phenotyping in type 2 diabetes: a clinical classification tool. Diabetes Metab Res Rev. 2018;34:e3005.

Article  PubMed  Google Scholar 

Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 2023;66:1765–79.

Article  CAS  PubMed  Google Scholar 

Mathieu C, Ahmadzai I. Incretins beyond type 2 diabetes. Diabetologia. 2023;66:1809–19. https://doi.org/10.1007/s00125-023-05980-x.

Article  CAS  PubMed  Google Scholar 

Aberer F, Pieber TR, Eckstein ML, Sourij H, Moser O. Glucose-lowering therapy beyond insulin in type 1 diabetes: a narrative review on existing evidence from randomized controlled trials and clinical perspective. Pharmaceutics. 2022;14:1180. https://www.mdpi.com/1999-4923/14/6/1180.

Anson M, Zhao SS, Austin P, Ibarburu GH, Malik RA, Alam U. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. Diabetologia. 2023;66:1869–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

International Diabetes Federation. IDF diabetes atlas. Type 1 diabetes estimates in children and adults. https://diabetesatlas.org/atlas/t1d-index-2022/. Accessed

Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of Type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44:2589–625. https://doi.org/10.2337/dci21-0043.

Article  CAS  PubMed  Google Scholar 

Chong B, Kong G, Shankar K, et al. The global syndemic of metabolic diseases in the young adult population: a consortium of trends and projections from the Global Burden of Disease 2000–2019. Metabolism. 2023;141: 155402.

Article  CAS  PubMed  Google Scholar 

Fährmann ER, Adkins L, Loader CJ, et al. Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes Res Clin Pract. 2015;107:280–9.

Article  PubMed  Google Scholar 

Lind M, Svensson A-M, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972–82.

Article  PubMed  Google Scholar 

Coles B, Zaccardi F, Hvid C, Davies MJ, Khunti K. Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: a real-world study of patients followed for up to 19 years. Diabetes Obes Metab. 2021;23:218–27.

Article  CAS  PubMed  Google Scholar 

Kueh MTW, Chew NWS, Al-Ozairi E, le Roux CW. The emergence of obesity in type 1 diabetes. Int J Obes. 2005;2024(48):289–301.

Google Scholar 

Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288–98. https://www.nature.com/articles/s41574-019-0176-8

Ansari S, Haboubi H, Haboubi N. Adult obesity complications: challenges and clinical impact. Ther Adv Endocrinol Metab. 2020;11:2042018820934955.

Article  PubMed  PubMed Central  Google Scholar 

Vilarrasa N, San Jose P, Rubio MÁ, Lecube A. Obesity in patients with type 1 diabetes: links, risks and management challenges. Diabetes Metab Syndr Obes Targets Ther. 2021;14:2807–27.

Article  Google Scholar 

Freeby M, Lane K. Treating obesity in type 1 diabetes mellitus—review of efficacy and safety. Curr Opin Endocrinol Diabetes Obes. 2024;31:1–7.

PubMed  Google Scholar 

Janez A, Muzurovic E, Stoian AP, et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: recommendations from a Eastern and Southern Europe diabetes expert group. Int J Cardiol. 2022;365:8–18.

Article  PubMed  Google Scholar 

Janez A, Muzurovic E, Bogdanski P, et al. Modern management of cardiometabolic continuum: from overweight/obesity to prediabetes/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe diabetes and obesity expert group. Diabetes Ther. 2024;15:1865–92. https://doi.org/10.1007/s13300-024-01615-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011;96:1654–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bielka W, Przezak A, Molęda P, Pius-Sadowska E, Machaliński B. Double diabetes—when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition. Cardiovasc Diabetol. 2024;23:62.

Article  PubMed  PubMed Central  Google Scholar 

Tan Q, Akindehin SE, Orsso CE, et al. Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes. Front Endocrinol. 2022;13: 838410.

Article  Google Scholar 

Chia CW, Egan JM. Incretins in obesity and diabetes. Ann N Y Acad Sci. 2020;1461:104–26.

Article  CAS  PubMed  Google Scholar 

Muzurović EM, Volčanšek Š, Tomšić KZ, et al. Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver disease-current evidence. J Cardiovasc Pharmacol Ther. 2022;27:10742484221146372.

Article  PubMed  Google Scholar 

Gutgesell RM, Nogueiras R, Tschöp MH, Müller TD. Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes. Diabetes Ther. 2024;15:1069–84. https://doi.org/10.1007/s13300-024-01566-x.

Article  PubMed  PubMed Central  Google Scholar 

Jensterle M, Rizzo M, Janež A. Semaglutide in obesity: unmet needs in men. Diabetes Ther. 2023;14:461–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67:564–600.

Article  CAS  PubMed  Google Scholar 

Lutz TA. Creating the amylin story. Appetite. 2022;172:105965.

Article  PubMed  Google Scholar 

Lutz TA. The interaction of amylin with other hormones in the control of eating. Diabetes Obes Metab. 2013;15:99–111.

Article  CAS  PubMed  Google Scholar 

Hieronymus L, Griffin S. Role of amylin in type 1 and type 2 diabetes. Diabetes Educ. 2015;41:47S-56S.

Article  PubMed  Google Scholar 

Bower RL, Hay DL. Amylin structure–function relationships and receptor pharmacology: implications for amylin mimetic drug development. Br J Pharmacol. 2016;173:1883. https://pmc.ncbi.nlm.nih.gov/articles/PMC4882495/.

Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 1987;84:8628–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clark A, Lewis CE, Willis AC, Cooper GJS, Morris JF, Reid KBM, et al. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet. 1987;330:231–4.

Article  Google Scholar 

Dai Z, Ben-Younis A, Vlachaki A, Raleigh D, Thalassinos K. Understanding the structural dynamics of human islet amyloid polypeptide: advancements in and applications of ion-mobility mass spectrometry. Biophys Chem. 2024;312:107285.

Article  CAS  PubMed  PubMed Central